HCRT and migraine disorder: Preclinical work has suggested that the orexins may be involved in migraine via their roles in sleep and pain [82–84], and whilst a clinical trial of a dual orexin antagonist filorexant administered daily at night was not successful [85], more targeted therapeutics and different dosing regimens within this system may be a future therapeutic option for migraine.